Hazard - P - B - T - Risk Exempt
Assessment report for Praxbind (idarucizumab), 24 September 2015, EMA/713107/2015.
"The Fab idarucizumab is a protein which is unlikely to result in significant risk to the environment. This was agreed by the CHMP."
Fass environmental information for Praxbind from Boehringer Ingelheim (downloaded 2019-09-04).
The use of amino acids, proteins and peptides is not expected to have any environmental impact.
According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00),vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
Author: Health and Medical Care Administration, Region Stockholm